Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) – SEC Form 4 filing dated 07/07/2025
Director Meghan V. Joyce reported the acquisition of 66 common shares on 07/04/2025 through the settlement of previously granted Restricted Stock Units (RSUs). The RSUs carried a $0 conversion price, so no cash changed hands. Following the transaction, Joyce’s direct beneficial ownership increases to 11,216 common shares.
The underlying RSU award vested 25 % on 08/04/2022, with the remaining 75 % vesting in equal monthly installments over three years (through 08/04/2025). No derivative securities were disposed of, and the transaction was coded “M” (acquisition from the company without open-market purchase).
The filing is routine, involves a small share count relative to Guardant Health’s outstanding shares, and contains no financial performance information or strategic disclosures.
Guardant Health, Inc. (GH) – Form 4 filing (07/02/2025)
Chief Information Officer Kumud Kalia reported routine equity transactions tied to the vesting of previously granted restricted stock units (RSUs) on July 1 2025:
- 2,691 common shares were issued upon the automatic conversion of RSUs (Transaction Code M) at a zero exercise price.
- 1,365 shares were simultaneously surrendered to the company to cover statutory tax-withholding obligations (Transaction Code F) at a market price of $50.71.
- After the net share settlement, Kalia’s direct ownership increased by 1,326 shares to a total of 20,500 common shares.
The derivative table shows that the executive still holds 8,035 unvested RSUs from a November 7 2022 grant and 5,419 unvested RSUs from a December 13 2023 grant, each vesting quarterly over their remaining terms. No open-market sales or purchases were reported beyond the withheld shares, indicating that the insider retained all newly vested stock net of taxes.
This filing reflects standard equity-compensation activity; it does not disclose any new option grants, cash transactions, or information that would materially alter Guardant Health’s financial outlook. The scale of the net acquisition is immaterial relative to the company’s total shares outstanding, but it modestly increases insider alignment.
Guardant Health, Inc. (GH) – Form 4 insider transaction, filed 2 Jul 2025
Chief Commercial Officer Chris Freeman reported automatic vesting of two restricted-stock-unit (RSU) tranches on 1 Jul 2025:
- 1,929 shares from a November 2022 RSU grant.
- 1,667 shares from a December 2023 RSU grant.
Both conversions were coded “M” (exempt), reflecting zero exercise price. To cover associated tax obligations, the company withheld 1,532 shares (Code “F”) at a market price of $50.71.
After the transactions, Freeman’s direct ownership rose by a net ≈2,064 shares to 48,821 shares. No open-market purchases or discretionary sales occurred; all movements relate to routine equity compensation vesting and withholding.
On 1 July 2025, Guardant Health, Inc. (GH) filed a Form 4 disclosing routine equity compensation activity by Chief Technology Officer Darya Chudova. Two tranches of previously granted restricted stock units (RSUs) converted into 3,007 common shares at a zero exercise price. To satisfy statutory tax-withholding requirements, 1,525 shares were immediately withheld and disposed of at a market price of $50.71. The net effect is an incremental increase of 1,482 shares, lifting Chudova’s direct beneficial ownership to 81,294 shares.
The derivative table shows Chudova still holds 15,033 unvested RSUs—6,696 from a November 7 2022 grant that vests quarterly through October 2026, and 8,337 from a December 13 2023 grant that vests quarterly through October 2026. Both awards follow typical time-based vesting schedules, and no open-market transactions, 10b5-1 trades, or discretionary sales were reported.
Because the activity stems from standard RSU vesting rather than a voluntary purchase or sale, the filing carries minimal direct market impact. Still, the absence of net selling and the modest increase in insider ownership may be viewed as slightly constructive for investor sentiment.
Guardant Health (GH) – Form 4 filing dated 07/02/2025 discloses routine equity activity by Chief Financial Officer Michael Brian Bell linked to previously granted restricted stock units (RSUs).
- On 07/01/2025, 2,084 RSUs vested (code M). These were converted into common shares at no cash cost.
- To satisfy tax-withholding, 1,057 shares were automatically withheld and disposed of at $50.71 per share (code F).
- Net result: the CFO’s direct common-stock holdings increased by 1,027 shares to 43,028 shares; he retains 10,421 unvested RSUs.
No open-market purchases or discretionary sales occurred; the transactions appear strictly administrative and are consistent with the original three-year vesting schedule of the December 13, 2023 RSU grant.
Guardant Health, Inc. (GH) – Form 4 insider transaction summary for Co-CEO & Director AmirAli Talasaz. The filing covers activity on 06/30/2025 and 07/01/2025.
- Option / RSU exercises (Code M): 4,815 shares were issued on 06/30/2025 and 23,997 shares on 07/01/2025 at a $0 exercise price, representing vested restricted stock units.
- Shares withheld for taxes (Code F): 2,441 shares (avg. $52.04) on 06/30/2025 and 12,162 shares (avg. $50.71) on 07/01/2025 were retained by the company to satisfy withholding obligations.
- Open-market sales (Code S): 72,068 shares sold at a weighted avg. price of $50.6715 (price range $50.08-$51.07) and 27,932 shares sold at a weighted avg. price of $51.4047 (range $51.08-$51.94) on 07/01/2025. All sales were executed under a Rule 10b5-1 trading plan adopted on 12/17/2024.
- Net effect: Beneficial ownership fell from 2,074,271 to 1,983,665 shares, a decrease of 90,606 shares (~4.4% of the prior direct holdings). Derivative holdings now show 9,629 and 143,983 unvested RSUs under two separate awards.
The transactions were routine equity award vesting, tax withholding, and pre-planned sales. No cash was paid for option/RSU exercises, and the filing does not disclose any changes to company fundamentals or guidance.